Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!